- Home
- TGHL vs SERA Comparison
TGHL vs SERA Comparison
Compare TGHL & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGHL
- SERA
- Stock Information
- Founded
- TGHL 2020
- SERA 2008
- Country
- TGHL Singapore
- SERA United States
- Employees
- TGHL N/A
- SERA N/A
- Industry
- TGHL EDP Services
- SERA Precision Instruments
- Sector
- TGHL Technology
- SERA Health Care
- Exchange
- TGHL Nasdaq
- SERA Nasdaq
- Market Cap
- TGHL 42.0M
- SERA 90.6M
- IPO Year
- TGHL 2025
- SERA 2021
- Fundamental
- Price
- TGHL $1.64
- SERA $3.21
- Analyst Decision
- TGHL
- SERA
- Analyst Count
- TGHL 0
- SERA 0
- Target Price
- TGHL N/A
- SERA N/A
- AVG Volume (30 Days)
- TGHL 189.5K
- SERA 58.6K
- Earning Date
- TGHL 01-01-0001
- SERA 11-05-2025
- Dividend Yield
- TGHL N/A
- SERA N/A
- EPS Growth
- TGHL N/A
- SERA N/A
- EPS
- TGHL N/A
- SERA N/A
- Revenue
- TGHL $173,668.00
- SERA $108,000.00
- Revenue This Year
- TGHL N/A
- SERA $217.92
- Revenue Next Year
- TGHL N/A
- SERA $479.25
- P/E Ratio
- TGHL N/A
- SERA N/A
- Revenue Growth
- TGHL 84.40
- SERA 0.94
- 52 Week Low
- TGHL $1.56
- SERA $1.37
- 52 Week High
- TGHL $4.25
- SERA $9.13
- Technical
- Relative Strength Index (RSI)
- TGHL N/A
- SERA 56.31
- Support Level
- TGHL N/A
- SERA $2.87
- Resistance Level
- TGHL N/A
- SERA $3.29
- Average True Range (ATR)
- TGHL 0.00
- SERA 0.21
- MACD
- TGHL 0.00
- SERA -0.00
- Stochastic Oscillator
- TGHL 0.00
- SERA 59.52
About TGHL The GrowHub Limited Class A Ordinary Shares
The Growhub Ltd operates at the intersection of technology and supply chain management in the food industry, focusing on enhancing product traceability and authenticity. With a commitment to innovation and sustainability, It has developed a multi-faceted approach to address industry challenges. its business currently comprises two main divisions, which are the GrowHub Platform and its product trading facilitation offering.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.